Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$81.63 USD
-2.49 (-2.96%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $81.63 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLNO 81.63 -2.49(-2.96%)
Will SLNO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLNO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLNO
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
SLNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Other News for SLNO
Soleno Therapeutics's Earnings: A Preview
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 ...
Soleno Therapeutics Inc (SLNO) Announces Upcoming Financial Results and Operational Highlights ...